Luca Issi
Stock Analyst at RBC Capital
(0.13)
# 4,705
Out of 5,060 analysts
711
Total ratings
35.1%
Success rate
-5.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Reiterated: Hold | $130 | $218.01 | -40.37% | 42 | Oct 16, 2026 | |
| AGIO Agios Pharmaceuticals | Reiterated: Hold | $32 | $31.32 | +2.17% | 9 | Oct 8, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $350 → $345 | $231.83 | +48.82% | 66 | Oct 8, 2026 | |
| AMGN Amgen | Reiterated: Buy | $400 → $430 | $432.49 | -0.58% | 14 | Oct 8, 2026 | |
| ARGX argenx SE | Reiterated: Buy | $1,100 | $819.14 | +34.29% | 14 | Oct 8, 2026 | |
| ASND Ascendis Pharma | Reiterated: Buy | $290 | $225.24 | +28.75% | 18 | Oct 8, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $100 | $66.39 | +50.63% | 6 | Oct 8, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Hold | $62 | $54.68 | +13.39% | 38 | Oct 8, 2026 | |
| IONS Ionis Pharmaceuticals | Reiterated: Buy | $85 | $42.94 | +97.95% | 42 | Oct 8, 2026 | |
| RARE Ultragenyx Pharmaceutical | Reiterated: Hold | $19 | $14.54 | +30.67% | 22 | Oct 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $10 → $1 | $0.4699 | +112.81% | 24 | Oct 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $65 → $48 | $21.78 | +120.39% | 45 | Oct 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $5.53 | +225.50% | 1 | Sep 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $30 | $14.25 | +110.53% | 13 | Sep 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 | $55.90 | +78.89% | 41 | Aug 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.31 | +587.02% | 33 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $2.64 | +657.58% | 15 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $8 → $10 | $8.49 | +17.79% | 16 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $15 | $11.42 | +31.35% | 37 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $6.93 | +174.37% | 40 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $26 | $23.47 | +10.78% | 26 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 | $2.35 | +70.21% | 27 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $50 | $49.25 | +1.52% | 30 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $3.13 | +379.23% | 28 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 → $4 | $3.65 | +9.59% | 6 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 | $0.1102 | +1,714.88% | 21 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 → $11 | $9.28 | n/a | 17 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $54 | $7.52 | n/a | 13 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 → $3 | $3.28 | n/a | 7 | Mar 21, 2023 |
Moderna
Oct 16, 2026
Reiterated: Hold
Price Target: $130
Current: $218.01
Upside: -40.37%
Agios Pharmaceuticals
Oct 8, 2026
Reiterated: Hold
Price Target: $32
Current: $31.32
Upside: +2.17%
Alnylam Pharmaceuticals
Oct 8, 2026
Reiterated: Buy
Price Target: $350 → $345
Current: $231.83
Upside: +48.82%
Amgen
Oct 8, 2026
Reiterated: Buy
Price Target: $400 → $430
Current: $432.49
Upside: -0.58%
argenx SE
Oct 8, 2026
Reiterated: Buy
Price Target: $1,100
Current: $819.14
Upside: +34.29%
Ascendis Pharma
Oct 8, 2026
Reiterated: Buy
Price Target: $290
Current: $225.24
Upside: +28.75%
BridgeBio Pharma
Oct 8, 2026
Reiterated: Buy
Price Target: $100
Current: $66.39
Upside: +50.63%
BioMarin Pharmaceutical
Oct 8, 2026
Reiterated: Hold
Price Target: $62
Current: $54.68
Upside: +13.39%
Ionis Pharmaceuticals
Oct 8, 2026
Reiterated: Buy
Price Target: $85
Current: $42.94
Upside: +97.95%
Ultragenyx Pharmaceutical
Oct 8, 2026
Reiterated: Hold
Price Target: $19
Current: $14.54
Upside: +30.67%
Oct 6, 2026
Downgraded: Hold
Price Target: $10 → $1
Current: $0.4699
Upside: +112.81%
Oct 2, 2026
Rated: Buy
Price Target: $65 → $48
Current: $21.78
Upside: +120.39%
Sep 16, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $5.53
Upside: +225.50%
Sep 8, 2026
Reiterated: Buy
Price Target: $35 → $30
Current: $14.25
Upside: +110.53%
Aug 30, 2026
Reiterated: Buy
Price Target: $100
Current: $55.90
Upside: +78.89%
Aug 12, 2026
Reiterated: Buy
Price Target: $9
Current: $1.31
Upside: +587.02%
Aug 12, 2026
Reiterated: Buy
Price Target: $20
Current: $2.64
Upside: +657.58%
Aug 7, 2026
Reiterated: Hold
Price Target: $8 → $10
Current: $8.49
Upside: +17.79%
Aug 6, 2026
Reiterated: Hold
Price Target: $15
Current: $11.42
Upside: +31.35%
Aug 6, 2026
Reiterated: Buy
Price Target: $19
Current: $6.93
Upside: +174.37%
Aug 5, 2026
Reiterated: Hold
Price Target: $26
Current: $23.47
Upside: +10.78%
Aug 5, 2026
Reiterated: Hold
Price Target: $4
Current: $2.35
Upside: +70.21%
Aug 3, 2026
Reiterated: Hold
Price Target: $50
Current: $49.25
Upside: +1.52%
Jul 30, 2026
Reiterated: Buy
Price Target: $15
Current: $3.13
Upside: +379.23%
Jun 2, 2026
Reiterated: Hold
Price Target: $10 → $4
Current: $3.65
Upside: +9.59%
May 14, 2026
Reiterated: Hold
Price Target: $2
Current: $0.1102
Upside: +1,714.88%
Nov 13, 2024
Reiterated: Buy
Price Target: $9 → $11
Current: $9.28
Upside: n/a
May 11, 2023
Reiterated: Hold
Price Target: $3 → $54
Current: $7.52
Upside: n/a
Mar 21, 2023
Reiterated: Hold
Price Target: $4 → $3
Current: $3.28
Upside: n/a